Segment Information (Tables)

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

Schedule of Financial Information by Segment

Financial information by segment is as follows:

	Year Ended December 31, 2024
	Cell Therapy			BioBanking		Degenerative Disease		Total
Net revenues	$	688		$	5,140	$	48,392	$	54,220
Cost of revenues (excluding amortization of acquired intangible assets)		—			1,172		13,817		14,989
Direct expenses		15,807			1,673		20,846		38,326
Segment contribution		(15,119	)		2,295		13,729		905
Other general and administrative expenses									37,703
Indirect expenses									1,560	(a)
Loss from operations								$	(38,358	)
Other expenses									(19,534	)
Loss before income taxes								$	(57,892	)
(a) Components of indirect expenses
Change in fair value of contingent consideration liability								$	(193	)
Amortization									1,753
Total other								$	1,560

	Year Ended December 31, 2023
	Cell Therapy			BioBanking		Degenerative Disease			Total
Net revenues	$	—		$	5,441	$	17,330		$	22,771
Cost of revenues (excluding amortization of acquired intangible assets)		—			1,650		14,366			16,016
Direct expenses		28,694			1,752		9,720			40,166
Segment contribution		(28,694	)		2,039		(6,756	)		(33,411	)
Other general and administrative expenses										40,876
Indirect expenses										118,001	(a)
Loss from operations									$	(192,287	)
Other expenses										(3,998	)
Loss before income taxes									$	(196,285	)
(a) Components of indirect expenses
Change in fair value of contingent consideration liability									$	(104,339	)
Goodwill impairment										112,347
IPR&D impairment										107,800
Amortization										2,193
Total other									$	118,001